TCI Wealth Advisors, Inc. - HAEMONETICS CORP ownership

HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 247 filers reported holding HAEMONETICS CORP in Q4 2017. The put-call ratio across all filers is 1.58 and the average weighting 0.1%.

Quarter-by-quarter ownership
TCI Wealth Advisors, Inc. ownership history of HAEMONETICS CORP
ValueSharesWeighting
Q1 2023$17,378
+5.2%
2100.0%0.00%0.0%
Q4 2022$16,516
+3.2%
2100.0%0.00%
-33.3%
Q3 2022$16,000
+23.1%
210
+1.4%
0.00%
+50.0%
Q2 2022$13,0000.0%2070.0%0.00%0.0%
Q1 2022$13,000
+1200.0%
207
+935.0%
0.00%
Q4 2021$1,000
-88.9%
20
-84.8%
0.00%
-100.0%
Q3 2021$9,000
-10.0%
132
-8.3%
0.00%
-50.0%
Q2 2021$10,000
+400.0%
144
+620.0%
0.00%
+100.0%
Q1 2021$2,0000.0%200.0%0.00%0.0%
Q4 2020$2,0000.0%200.0%0.00%0.0%
Q3 2020$2,0000.0%200.0%0.00%0.0%
Q2 2020$2,0000.0%200.0%0.00%0.0%
Q1 2020$2,0000.0%200.0%0.00%0.0%
Q4 2019$2,000
-33.3%
200.0%0.00%0.0%
Q3 2019$3,000
+50.0%
200.0%0.00%0.0%
Q2 2019$2,0000.0%200.0%0.00%0.0%
Q1 2019$2,0000.0%200.0%0.00%0.0%
Q4 2018$2,000
-33.3%
20
-28.6%
0.00%0.0%
Q3 2018$3,000
-25.0%
28
-36.4%
0.00%
-50.0%
Q2 2018$4,000
+300.0%
44
+120.0%
0.00%
Q1 2018$1,0000.0%200.0%0.00%
Q4 2017$1,0000.0%200.0%0.00%
Q3 2017$1,0000.0%200.0%0.00%
-100.0%
Q2 2017$1,0000.0%200.0%0.00%0.0%
Q1 2017$1,0000.0%200.0%0.00%0.0%
Q4 2016$1,0000.0%200.0%0.00%0.0%
Q3 2016$1,0000.0%200.0%0.00%0.0%
Q2 2016$1,000200.00%
Other shareholders
HAEMONETICS CORP shareholders Q4 2017
NameSharesValueWeighting ↓
Nitorum Capital, L.P. 413,122$16,608,0004.78%
Altalis Capital Management LLC 88,055$3,540,0003.97%
RUTABAGA CAPITAL MANAGEMENT LLC/MA 513,619$20,647,0003.54%
Black Creek Investment Management Inc. 1,118,613$44,968,0003.46%
HealthCor Management, L.P. 1,150,000$46,230,0002.61%
Van Berkom & Associates Inc. 1,136,971$45,706,0001.83%
AMERICAN CAPITAL MANAGEMENT INC 567,896$22,829,0001.77%
FULLER & THALER ASSET MANAGEMENT, INC. 2,062,539$82,914,0001.25%
Legato Capital Management LLC 1,336$53,707,0000.97%
HEARTLAND ADVISORS INC 351,314$14,123,0000.78%
View complete list of HAEMONETICS CORP shareholders